Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michele Morari

Showing results (21-30 of 93) with videos related to

Pageof 10
Sort By:
Brain Research|July 20, 2021
l-DOPA promotes striatal dopamine release through D1 receptors and reversal of dopamine transporterRiccardo Viaro, Francesco Longo, Fabrizio Vincenzi, et al.
Neuropharmacology|May 7, 2013
Pharmacological and genetic evidence for pre- and postsynaptic D2 receptor involvement in motor responses to nociceptin/orphanin FQ receptor ligandsRiccardo Viaro, Mariangela Calcagno, Matteo Marti, et al.
Molecular and Cellular Neurosciences|October 27, 2005
Group-II metabotropic glutamate receptors negatively modulate NMDA transmission at striatal cholinergic terminals: role of P/Q-type high voltage activated Ca++ channels and endogenous dopamineFlora Mela, Matteo Marti, Chiara Fiorentini, et al.
Journal of Neurochemistry|October 23, 2002
Striatal dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptorsMatteo Marti, Flora Mela, Clementina Bianchi, et al.
Journal of Neurochemistry|October 19, 2010
Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson's disease: a behavioral and neurochemical study in reserpinized miceMattia Volta, Omar S Mabrouk, Simone Bido, et al.
British Journal of Pharmacology|October 25, 2019
Managing Parkinson's disease: moving ON with NOPDaniela Mercatelli, Erwan Bezard, Roberto Eleopra, et al.
Neurobiology of Disease|August 10, 2014
Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with agingFrancesco Longo, Isabella Russo, Derya R Shimshek, et al.
Neurobiology of Disease|October 18, 2011
In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levelsFlora Mela, Matteo Marti, Simone Bido, et al.
Journal of Neurochemistry|December 9, 2004
Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate releaseMatteo Marti, Flora Mela, Remo Guerrini, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|September 26, 2014
Stimulation of δ opioid receptor and blockade of nociceptin/orphanin FQ receptor synergistically attenuate parkinsonismOmar S Mabrouk, Riccardo Viaro, Mattia Volta, et al.
Pageof 10

Showing results (21-30 of 93) with videos related to

Sort By:
Pageof 10
Brain Research|July 20, 2021
l-DOPA promotes striatal dopamine release through D1 receptors and reversal of dopamine transporterRiccardo Viaro, Francesco Longo, Fabrizio Vincenzi, et al.
Neuropharmacology|May 7, 2013
Pharmacological and genetic evidence for pre- and postsynaptic D2 receptor involvement in motor responses to nociceptin/orphanin FQ receptor ligandsRiccardo Viaro, Mariangela Calcagno, Matteo Marti, et al.
Molecular and Cellular Neurosciences|October 27, 2005
Group-II metabotropic glutamate receptors negatively modulate NMDA transmission at striatal cholinergic terminals: role of P/Q-type high voltage activated Ca++ channels and endogenous dopamineFlora Mela, Matteo Marti, Chiara Fiorentini, et al.
Journal of Neurochemistry|October 23, 2002
Striatal dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptorsMatteo Marti, Flora Mela, Clementina Bianchi, et al.
Journal of Neurochemistry|October 19, 2010
Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson's disease: a behavioral and neurochemical study in reserpinized miceMattia Volta, Omar S Mabrouk, Simone Bido, et al.
British Journal of Pharmacology|October 25, 2019
Managing Parkinson's disease: moving ON with NOPDaniela Mercatelli, Erwan Bezard, Roberto Eleopra, et al.
Neurobiology of Disease|August 10, 2014
Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with agingFrancesco Longo, Isabella Russo, Derya R Shimshek, et al.
Neurobiology of Disease|October 18, 2011
In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levelsFlora Mela, Matteo Marti, Simone Bido, et al.
Journal of Neurochemistry|December 9, 2004
Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate releaseMatteo Marti, Flora Mela, Remo Guerrini, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|September 26, 2014
Stimulation of δ opioid receptor and blockade of nociceptin/orphanin FQ receptor synergistically attenuate parkinsonismOmar S Mabrouk, Riccardo Viaro, Mattia Volta, et al.
Pageof 10